Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Fmr LLC

Fmr LLC lessened its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 67.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,724,015 shares of the company’s stock after selling 3,605,931 shares during the period. Fmr LLC owned 2.76% of Fulcrum Therapeutics worth $6,155,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. National Bank of Canada FI boosted its holdings in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after buying an additional 4,000 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares during the period. SG Americas Securities LLC lifted its position in Fulcrum Therapeutics by 26.5% during the 3rd quarter. SG Americas Securities LLC now owns 33,019 shares of the company’s stock worth $118,000 after acquiring an additional 6,926 shares during the last quarter. Profund Advisors LLC bought a new position in Fulcrum Therapeutics in the 2nd quarter worth approximately $68,000. Finally, American Century Companies Inc. increased its holdings in shares of Fulcrum Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 104,371 shares of the company’s stock worth $647,000 after purchasing an additional 12,167 shares during the period. Institutional investors own 89.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on FULC shares. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a report on Thursday, September 12th. Stifel Nicolaus lowered Fulcrum Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the company from $22.00 to $3.00 in a research note on Thursday, September 12th. Bank of America lowered Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price target for the stock from $10.00 to $2.00 in a research report on Thursday, September 12th. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.33.

Fulcrum Therapeutics Price Performance

FULC stock opened at $4.03 on Friday. The company has a fifty day moving average price of $3.50 and a two-hundred day moving average price of $5.97. The stock has a market cap of $217.37 million, a price-to-earnings ratio of -13.00 and a beta of 2.14. Fulcrum Therapeutics, Inc. has a one year low of $2.86 and a one year high of $13.70.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.